Hospital Adoption and Pricing for Oncology Biosimilars

How have acquisition prices, reimbursement prices, and adoption of oncology biosimilars changed in recent years?In 66 139 patients with cancer between 2020 and 2024, hospital acquisition prices for 3 oncology biosimilars declined more rapidly than reimbursement prices, leading to an increase in hospital margin revenues. The percentage share of biosimilars increased to 93% for bevacizumab, 87% for trastuzumab, and 84% for rituximab by 2024.Declining prices for oncology biosimilars have enabled hospitals to increase markup margins and have been associated with rapid increases in adoption.

Corresponding Author: James C. Robinson, PhD, University of California, Berkeley, Berkeley, CA 94720-7360 (james.robinson@berkeley.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.